| 產(chǎn)品編號(hào) | BIO0967SM | 
| 英文名稱 | Anti-BCMA & CD3 Reference Antibody (Elranatamab Biosimilar) | 
| 別 名 | TNFRSF17 / BCMA / CD269 & CD3; Elranatamab | 
| 抗體來源 | |
| 克隆類型 | Monoclonal | 
| 交叉反應(yīng) | Human | 
| 產(chǎn)品應(yīng)用 | 
 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.  | 
| 理論分子量 | 145.44kDa | 
| 性 狀 | Lyophilized | 
| 亞 型 | IgG-like | 
| 純化方法 | Protein A | 
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 | 
| 保存條件 | -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles. | 
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. | 
| PubMed | PubMed | 
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 | 
 
Co-incubation of Elranatamab-Bcmm with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Elranatamab-Bcmm was able to activate the NF-AT signaling pathway, and the EC50 was 0.081 nM.
 
Elranatamab-Bcmm bound to huCD3e-jurkat cells,  and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huCD3e-jurkat cells, and the EC50 was 64.990 nM.
 
Elranatamab-Bcmm bound to huBCMA-HEK293 cells,  and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and the EC50 was 1.263 nM.
 
Elranatamab-Bcmm bound to BCMA protein,  and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Elranatamab-Bcmm bound to huBCMA-ECD-His , and the EC50 was 0.055 nM.
 
Anti-BCMA & CD3 Reference Antibody (Elranatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
 
 |